08:25 AM EDT, 10/14/2024 (MT Newswires) -- BioCryst Pharmaceuticals ( BCRX ) said Monday a study of berotralstat, which it markets under the brand name of Orladeyo, showed a significant reduction in hospitalizations, emergency room visits, and use of on-demand therapies for patients with hereditary angioedema in the US.

The company said that the study of berotralstat will be presented at the Academy of Managed Care Pharmacy Nexus 2024 national meeting being held in Las Vegas, Nevada, this week.

Price: 7.59, Change: +0.16, Percent Change: +2.15